Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Legendre CM, et al. Among authors: licht c. N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981. N Engl J Med. 2013. PMID: 23738544 Free article. Clinical Trial.
Eculizumab and refractory membranoproliferative glomerulonephritis.
Radhakrishnan S, Lunn A, Kirschfink M, Thorner P, Hebert D, Langlois V, Pluthero F, Licht C. Radhakrishnan S, et al. Among authors: licht c. N Engl J Med. 2012 Mar 22;366(12):1165-6. doi: 10.1056/NEJMc1106619. N Engl J Med. 2012. PMID: 22435384 No abstract available.
Eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM, Licht C, Loirat C. Legendre CM, et al. Among authors: licht c. N Engl J Med. 2013 Oct 3;369(14):1379-80. doi: 10.1056/NEJMc1308826. N Engl J Med. 2013. PMID: 24088105 Free article. No abstract available.
An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome.
Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, Karpman D, Landau D, Langman C, Licht C, Pecoraro C, Riedl M, Siomou E, van de Kar N, Walle JV, Loirat C, Taylor CM. Johnson S, et al. Among authors: licht c. Pediatr Nephrol. 2014 Oct;29(10):1967-78. doi: 10.1007/s00467-014-2817-4. Epub 2014 May 11. Pediatr Nephrol. 2014. PMID: 24817340
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.
Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Licht C, et al. Kidney Int. 2015 May;87(5):1061-73. doi: 10.1038/ki.2014.423. Epub 2015 Feb 4. Kidney Int. 2015. PMID: 25651368 Free PMC article. Clinical Trial.
An international consensus approach to the management of atypical hemolytic uremic syndrome in children.
Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Frémeaux-Bacchi V; HUS International. Loirat C, et al. Among authors: licht c. Pediatr Nephrol. 2016 Jan;31(1):15-39. doi: 10.1007/s00467-015-3076-8. Epub 2015 Apr 11. Pediatr Nephrol. 2016. PMID: 25859752 Review.
The global aHUS registry: methodology and initial patient characteristics.
Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Schaefer F, Vande Walle J, Frémeaux-Bacchi V. Licht C, et al. BMC Nephrol. 2015 Dec 10;16:207. doi: 10.1186/s12882-015-0195-1. BMC Nephrol. 2015. PMID: 26654630 Free PMC article.
243 results